Worth reading
72In focus
Scored from 2 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
1931700
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Exercise status of the Fifth Series Stock Acquisition Rights with an exercise price adjustment clause (monthly report)
発行・処分する株式数
1,931,700 new shares (March 2026)
発行済株式総数
6.27% (1,931,700 shares delivered across all series / 30,797,500 listed shares outstanding as of the payment date for the issuance)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
¥90.90 or ¥103.50 (details of the adjustment clause and the adjustment floor: Not disclosed)
Number of Stock Acquisition Rights
Total issued: 76,370 rights; exercised in March 2026: 19,317 rights; remaining unexercised as of 31 March: 14,181 rights
Procedures under the Corporate Code of Conduct
The disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations.
Most recent equity financing
30 December 2024: Issuance of the Fifth Series Stock Acquisition Rights with an exercise price adjustment clause (amount details: Not disclosed)
| Item | Details |
|---|---|
| Type of issuance or disposal | Exercise status of the Fifth Series Stock Acquisition Rights with an exercise price adjustment clause (monthly report) |
| Number of shares to be issued or disposed of | 1,931,700 new shares (March 2026) |
| Dilution Rate | 6.27% (1,931,700 shares delivered across all series / 30,797,500 listed shares outstanding as of the payment date for the issuance) |
| Total number of issued shares | 37,088,900 shares (as of the end of the month preceding the relevant month) → Not disclosed |
| Exercise price | ¥90.90 or ¥103.50 (details of the adjustment clause and the adjustment floor: Not disclosed) |
| Number of Stock Acquisition Rights | Total issued: 76,370 rights; exercised in March 2026: 19,317 rights; remaining unexercised as of 31 March: 14,181 rights |
| Procedures under the Corporate Code of Conduct | The disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations. |
| Most recent equity financing | 30 December 2024: Issuance of the Fifth Series Stock Acquisition Rights with an exercise price adjustment clause (amount details: Not disclosed) |
Items this document does not state (20)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To report the monthly exercise status in March 2026 of the Fifth Series Stock Acquisition Rights issued on 30 December 2024.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.